Conquering Diseases

Testing Nurown To Treat Als

Description

This study will evaluate the effectivenes and safety of repeat administrations of injections of NurOwn as compared to Placebo given three times two months apart to participants with ALS. The study will consist of a pre-treatment period of up to 5 months, treatment period for 4 months and a follow up period of 3 months.

Overview

This study will evaluate the effectivenes and safety of repeated injections of NurOwn as compared to Placebo, given three times two months apart to participants with ALS. The study will consist of a pre-treatment periods of up to 5 months, treatment period for 4 months and a follow up period of 3 months. The previous phase tested the efficacy and safety of a single dose of the NurOwn treatment.

What we're hoping for

Evalute the satefy and efficacy of NurOwn as a treatment for ALS.

Additional Information

ClinicalTrials.gov Identifier: NCT03280056

 Principal Investigator

Robert H Brown, MD, PhD

UMass Memorial Health Care

 Study Contact

Catherine  Douthwright

508-856-6491

Catherine.Douthwright@umassmed.edu

 Location

UMMHC Memorial Campus

281 Lincoln St. 

Worcester,MA 01605

508-334-1000